ZBH vs. ALGN, SNN, EW, CAH, ICLR, RMD, ARGX, BIIB, WST, and MOH
Should you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include Align Technology (ALGN), Smith & Nephew (SNN), Edwards Lifesciences (EW), Cardinal Health (CAH), ICON Public (ICLR), ResMed (RMD), argenx (ARGX), Biogen (BIIB), West Pharmaceutical Services (WST), and Molina Healthcare (MOH). These companies are all part of the "medical" sector.
Align Technology (NASDAQ:ALGN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
Zimmer Biomet has higher revenue and earnings than Align Technology. Zimmer Biomet is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Align Technology had 18 more articles in the media than Zimmer Biomet. MarketBeat recorded 36 mentions for Align Technology and 18 mentions for Zimmer Biomet. Align Technology's average media sentiment score of 0.98 beat Zimmer Biomet's score of 0.45 indicating that Zimmer Biomet is being referred to more favorably in the news media.
88.4% of Align Technology shares are held by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are held by institutional investors. 0.6% of Align Technology shares are held by insiders. Comparatively, 1.0% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Zimmer Biomet received 124 more outperform votes than Align Technology when rated by MarketBeat users. However, 69.64% of users gave Align Technology an outperform vote while only 68.36% of users gave Zimmer Biomet an outperform vote.
Zimmer Biomet has a net margin of 13.85% compared to Zimmer Biomet's net margin of 11.80%. Zimmer Biomet's return on equity of 14.15% beat Align Technology's return on equity.
Align Technology presently has a consensus target price of $353.00, indicating a potential upside of 14.23%. Zimmer Biomet has a consensus target price of $139.39, indicating a potential upside of 16.79%. Given Align Technology's higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Align Technology.
Align Technology has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Summary
Align Technology beats Zimmer Biomet on 10 of the 18 factors compared between the two stocks.
Get Zimmer Biomet News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zimmer Biomet Competitors List
Related Companies and Tools
